About Us

Henry Publishing Group is an open access, multidisciplinary, international online publishing house, where it promotes publishing of the latest research in the fields of science. The Henry Publishing Group publishes all types of articles like research, reviews, short communication, case reports, mini review, opinion, commentaries, theory, editorials etc., to disseminate the knowledge globally. The article quality is standardized by the strictly blinded peer review process. Henry Publishing Group has been disciplined into Clinical, Medical and Life Sciences. The researchers unveil the laws of nature to the society by research. Henry Publishing Group intensifies sharing of knowledge to the scientific community and helps for the betterment of society. This lays the best forum for scientists, researchers, surgeons, physicians and pedagogy to communicate strengthen and expands the integrity of original research, also assists for the professional development.


IRAK4 Modulators for Treatment of Hematologic Malignancies

Short Cummunication

IRAK4 Modulators for Treatment of Hematologic Malignancies 

 


Mukherjee S1, Ramachandra M2 and Samajdar S3*

1,2,3 Aurigene Discovery Technologies Ltd., Bangalore, India

*Corresponding author: Susanta Samajdar, Aurigene Discovery Technologies Ltd., Bangalore, India, Tel: +91 80 7102 5320; E-mail: susanta_s@aurigene.com

Received: July 08, 2021; Accepted: July 13, 2021; Published: July 21, 2021

Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) plays an important role in Toll-Like Receptor (TLR) signalling and activation of innate immune responses. Impairment of the innate immunity is known to be associated with different inflammatory conditions and cancer. Although there had been significant progress in evaluation of IRAK4 modulators in clinic for the treatment of various inflammatory pathologies, there had been only limited exploration so far for evaluation of these agents for the treatment of cancers. Recent updates on the profile of some of these compounds have demonstrated that IRAK4 could be a fascinating and important target for the treatment of certain life-threatening cancers.  In this brief review article, we have compiled all the known IRAK4 modulators which are being actively developed to specifically address the unmet medical need in cancer. 

Citation: Mukherjee S, Ramachandra M, Samajdar S (2021) IRAK4 Modulators for Treatment of Hematologic Malignancies. J Hematol Hemother 6: 016.
Copyright: © 2021 Mukherjee S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

jn-img1